Skip to main content
SpringerLink
Log in

EMA recommends continued authorisation of three products

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. European Medicines Agency.Questions and answers on the review of Conbriza (bazedoxifene), PecFent (fentanyl) and Torisel (temsirolimus). Internet Document: [2 pages], 19 Jul 2012. Available from: URL: http://www.ema.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

EMA recommends continued authorisation of three products. React. Wkly. 1412, 2 (2012). https://doi.org/10.2165/00128415-201214120-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214120-00003

Keywords

Search

Navigation